 |
Prospector
Profile
1107-07
|
| |
| Neurobiological Technologies, Inc. |
NAICS |
541710 |
| 2000 Powell Street, Suite 800
Emeryville, CA 94608 |
Description |
Biotechnology |
| (510) 595-6000 |
Employees |
28 |
| http://www.ntii.com/ |
Revenue |
(mil) |
17.6720 |
| |
Income |
(mil) |
-14.1270 |
| |
Assets |
(mil) |
10.9210 |
| |
Liability |
(mil) |
33.0140 |
| |
(for the year ended 2007-06-30) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Neurobiological Technologies, Inc. had a net loss of $14,127,959 on revenues of $17,672,982 for the year ended June 30, 2007. This is much lower than the $27,838,954 net loss on $12,338,612 in revenues reported during the year ended June 30, 2006, and $24,977,567 net loss on $3,099,511 in revenues reported during the year ended June 30, 2005. As a result of its recurring losses, the Company has an accumulated deficit of $109,269,107, stockholder's deficit $22,093,038 and working capital deficit of $3,973,876 as of June 30, 2007.
|
| |
|
Intellectual Property:
The Company holds the exclusive worldwide marketing rights to Viprinex through a license from Abbott. Viprinex is protected by three patents covering the composition of matter and synthesis of the compound. In addition to patent protection, the Company relies upon trade secret protection for confidential and proprietary information. [SEC Filing 10-K 09-13-07]
|
| |
|
Description:
The biopharmaceutical company engages in the identification, acquisition, and development of central nervous system-related drug candidates.
|
| |
|
Officers:
Abraham E. Cohen (Chair); Paul E. Freiman (Pres., CEO & Dir.); Craig W. Carlson (VP & CFO); David E. Levy, M.D. (VP); Karl G. Trass (VP); Warren W. Wasiewski, M.D. (VP); Enoch Callaway, M.D. (Dir.); Ronald E. Cape, Ph.D. (Dir.); Theodore L. Eliot, Jr. (Dir.); William A. Fletcher (Dir.); F. Van Kasper (Dir.); Abraham D. Sofaer (Dir.); John B. Stuppin (Dir.)
|
| |
|
Auditor:
Ernst & Young LLP
|
| |
|
Securities:
Common Stock-Symbol NTII; NasdaqCM;
32,834,294 common shares outstanding as of September 7, 2007.
|
| |
| |
| |
| return to main page |
|
|
